FDA Approves First Oral Peptide for Plaque Psoriasis

The FDA has approved icotrokinra (Icotyde), an interleukin-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis.¹ This treatment, developed by Johnson & Johnson in collaboration with Protagonist Therapeutics, is designed for adults and pediatric patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.

The approval marks a meaningful shift in the oral small molecule and peptide therapeutic landscape.¹ Unlike existing oral agents, icotrokinra is a targeted oral peptide, which has historically faced significant bioavailability and selectivity challenges in development. Its successful path through Phase III represents a proof of concept that peptide-based receptor antagonism can be delivered orally at therapeutic levels, a finding relevant to pipeline programs exploring similar modalities.

The drug works by binding to the IL-23 receptor with high affinity, inhibiting downstream signaling in human T cells.¹ The clinical significance of receptor occupancy data is noted as unknown, but the mechanism positions icotrokinra at the same biological target as several approved injectable biologics.

What Does the Clinical Evidence Base Look Like?

The approval rests on the Iconic program, a Phase III development package spanning five studies and approximately 2,500 patients.¹ This dataset is notable for its scope and for the simultaneous enrollment of adult and adolescent populations, which often requires separate development tracks.

The package included duplicate head-to-head superiority trials (Iconic-Advance 1 and 2) against deucravacitinib, an approved oral tyrosine kinase 2 inhibitor.¹ Across those trials, roughly 70% of patients achieved an Investigator's Global Assessment score of 0 or 1 and approximately 55% reached a 90% improvement in Psoriasis Area and Severity Index score at Week 16. Running head-to-head trials in duplicate is an uncommon regulatory strategy and reflects a deliberate effort to generate robust comparative evidence.

Safety data through Week 16 showed adverse reaction rates within 1.1 percentage points of placebo, with no new safety signals identified through Week 52.¹ The most common adverse reactions were headache, nausea, cough, fungal infection, and fatigue. From a benefit-risk modeling perspective, the clean short-term profile, combined with a once-daily oral regimen taken on an empty stomach, presents a favorable adherence scenario compared with injectable alternatives.

"With new guidance from the International Psoriasis Council that clarifies when to move beyond cycling on topical treatments to systemic therapy, an innovative option like ICOTYDE is a potential game-changer for many adult and adolescent patients," said Linda Stein Gold, MD, director of Dermatology Clinical Research, Henry Ford Health, in a press release.¹

What Are the Downstream Implications for the Pipeline?

Johnson & Johnson retains exclusive worldwide development and commercialization rights under its license and collaboration agreement with Protagonist.¹ Icotrokinra is now in active investigation across additional indications (psoriatic arthritis (two studies), ulcerative colitis, and Crohn's disease) meaning the manufacturing and regulatory infrastructure built for this approval will need to scale accordingly.

The oral peptide format raises specific process considerations around stability, formulation, and GMP production that differ from both small molecules and conventional biologics.¹ The fact that the molecule can be dispersed in water and is dosed on an empty stomach suggests formulation constraints that likely shaped the development and manufacturing strategy.

"At Johnson & Johnson, we are harnessing our scientific expertise to transform cutting-edge science into meaningful solutions for patients," said John Reed, MD, PhD, executive vice president, R&D, Innovative Medicine, Johnson & Johnson, in the press release.¹ "ICOTYDE is a fundamentally different treatment with the potential to redefine what physicians and patients can expect from psoriasis treatment. The approval of ICOTYDE represents a pivotal moment for people with plaque psoriasis.”

How far Does the Oral Peptide Precedent Extend Beyond Psoriasis?

The icotrokinra approval arrives alongside broader momentum in Johnson & Johnson's targeted therapy pipeline.² At the European Association of Urology's 2026 Annual Meeting, the company presented Phase I results for erdafitinib intravesical drug-releasing system (Erda-iDRS), an investigational intravesical delivery system designed to release the kinase inhibitor erdafitinib directly into the bladder over three months, which minimizes systemic exposure while sustaining localized drug levels.

In 62 patients with recurrent intermediate-risk non-muscle-invasive bladder cancer harboring fibroblast growth factor receptor alterations, the complete response rate reached 89%, with a median response duration of 18 months.²

"The high and durable complete responses demonstrated with Erda-iDRS highlight the opportunity to deliver a targeted therapy to these patients," said Christopher Cutie, M.D., Vice President, Disease Area Leader, Bladder Cancer, Johnson & Johnson, in a press release.² Phase III studies are ongoing.

References

1. Johnson & Johnson. FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide. News release. March 17, 2026. Accessed March 18, 2026. https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide
2. ​Johnson & Johnson. Johnson & Johnson highlights promising first-in-human ERDA-IDRS (formerly TAR-210) results in intermediate-risk non–muscle-invasive bladder cancer. News release. March 18, 2026. Accessed March 18, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer